Pediatrix Medical Group, Inc.

MD

NYSE; healthcare; SIC 8060, Services-Hospitals; CIK 0000893949

C

middle fifth of 369 graded peers in healthcare

rank 170 of 369; percentile 45.9; sampling error 2.5 points; lower is stronger

A B C D E

C, the tortoise



Scoreboard	
Profitability	C percentile 46.9
Solvency	C percentile 47.8
Growth and financing	C percentile 44.6
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $2.2B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	8 of 14
Graded from	filings received through Feb 19, 2026 256 days before the rescan; latest periodic filing 10-Q received Oct 29, 2026
Last close	$29.79 2026-10-30; market equity $2.3B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 19, 2026

-"Geographic Coverage." Adverse changes or conditions affecting these particular states, such as healthcare reforms, changes in laws and regulations, increases in unreimbursed services arising from services furnished to undocumented noncitizens, reduced Medicaid eligibility or reimbursements and government investigations, economic conditions, weather conditions, and natural disasters may have an adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 46.9						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						
Return on invested capital	14.6%	9.3%		31.5	74	2025-12-31
Accruals ratio	(4.8%)	(6.6%)		62.3	803	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 47.8						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	2.05	(0.35)		28.6	748	2025-12-31
Net debt to EBITDA	0.85x	1.82x		37.8	75	2025-12-31
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	1.66x	2.92x		77.1	829	2025-12-31
Growth and financing, sleeve percentile 44.6						
Revenue growth, three-year compound	(1.0%)	10.1%		73.7	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 0						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	(1.5%)	2.2%		54.8	696	2025-12-31
Net share issuance, one year	(3.3%)	2.5%		5.2	631	2026-02-13

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
165	Davita Inc. (DVA)	44.6	C	
166	Pacira BioSciences, Inc. (PCRX)	44.8	C	
167	Innoviva, Inc. (INVA)	45.1	C	
168	Integer Holdings Corp. (ITGR)	45.4	C	
169	Repligen Corp. (RGEN)	45.7	C	late filer, fortress balance sheet
170	Pediatrix Medical Group, Inc. (MD)	45.9	C	
171	Lensar, Inc. (LNSR)	46.2	C	
172	Zimmer Biomet Holdings, Inc. (ZBH)	46.5	C	
173	Orasure Technologies Inc. (OSUR)	46.7	C	
174	Anika Therapeutics, Inc. (ANIK)	47.0	C	fortress balance sheet
175	Enovis Corp. (ENOV)	47.3	C	

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	51.6%	(2.2%)	78
Distance from 52-week high	0.0%	(28.7%)	95
EBIT to enterprise value	8.6%	(1.4%)	88
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.36	0.28	58

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sales to price	0.82	0.30	79
Composite equity issuance, five years	(9.2%)	20.5%	16
Relative strength against the sector, log excess return	0.25	(0.19)	78

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$311.9M
Operating cash flow, four quarters	$226.9M
Months of runway	not finite
Days since last periodic filing	4 (10-Q received Oct 29, 2026)
Median daily dollar volume, 63 sessions	$18.8M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	$208.8M	2025-12-31	2026-02-19	10-K	26-058074
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$216.4M	2025-12-31	2026-02-19	10-K	26-058074
3	income tax	us-gaap:IncomeTaxExpenseBenefit	$51.0M	2025-12-31	2026-02-19	10-K	26-058074
4	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$570.5M	2025-12-31	2026-02-19	10-K	26-058074
5	book equity	us-gaap:StockholdersEquity	$865.9M	2025-12-31	2026-02-19	10-K	26-058074
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$375.2M	2025-12-31	2026-02-19	10-K	26-058074
7	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$597.1M	2024-12-31	2026-02-19	10-K	26-058074
8	book equity	us-gaap:StockholdersEquity	$764.9M	2024-12-31	2026-02-19	10-K	26-058074
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$229.9M	2024-12-31	2026-02-19	10-K	26-058074
10	net income	us-gaap:NetIncomeLoss	$165.4M	2025-12-31	2026-02-19	10-K	26-058074
11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$271.1M	2025-12-31	2026-02-19	10-K	26-058074
12	assets	us-gaap:Assets	$2.2B	2025-12-31	2026-02-19	10-K	26-058074
13	assets	us-gaap:Assets	$2.2B	2024-12-31	2026-02-19	10-K	26-058074
14	current assets	us-gaap:AssetsCurrent	$763.5M	2025-12-31	2026-02-19	10-K	26-058074
15	current liabilities	us-gaap:LiabilitiesCurrent	$458.9M	2025-12-31	2026-02-19	10-K	26-058074
16	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$83.2M	2025-12-31	2026-02-19	10-K	26-058074
17	liabilities	us-gaap:Liabilities	$1.4B	2025-12-31	2026-02-19	10-K	26-058074
18	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$21.8M	2025-12-31	2026-02-19	10-K	26-058074
19	operating income	us-gaap:OperatingIncomeLoss	$7.3M	2023-12-31	2026-02-19	10-K	26-058074
20	interest expense	us-gaap:InterestExpense	$42.1M	2023-12-31	2024-02-20	10-K	24-016794
21	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$1.9B	2025-12-31	2026-02-19	10-K	26-058074
22	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$2.0B	2024-12-31	2026-02-19	10-K	26-058074
23	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$2.0B	2023-12-31	2026-02-19	10-K	26-058074
24	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$2.0B	2022-12-31	2025-02-20	10-K	25-023730
25	assets	us-gaap:Assets	$2.2B	2023-12-31	2025-02-20	10-K	25-023730
26	assets	us-gaap:Assets	$2.3B	2022-12-31	2024-02-20	10-K	24-016794
27	shares outstanding	dei:EntityCommonStockSharesOutstanding	83,001,072	2026-02-13	2026-02-19	10-K	26-058074

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

28	shares outstanding	dei:EntityCommonStockSharesOutstanding	85,829,575	2025-02-14	2025-02-20	10-K	25-023730